



Ivermectin Use in COVID-19 Prophylaxis

Prof. Abdelmonem Awad Hegazy,
Zagazig University & Misr University (MUST), Egypt

Abstract

Ivermectin is a safe, non-expensive and available drug. It has been previously approved by US FDA as a well-tolerable safe drug used previously for treatment and even mass prophylaxis of several parasitic drugs. It has been investigated in the current pandemic and proved a high effectiveness for chemoprophylaxis against SARS-CoV-2. Use of ivermectin can provide temporary protection that is not long-term immunity as occurs with a vaccine. Therefore, its use may be repeated. Ivermectin could be one of the hopes for ending the current dilemma of SARS-CoV-2 pandemic if used properly under medical supervision. It can be used for mass prophylaxis of the whole population at the same time especially for poor and middle-income countries that do not have the facilities to deliver good effective vaccines. Otherwise, it can be used as an emergency in case of exposure or contact with the patient and even used at the onset of infection. However, it may not be useful in treating severe cases because the virus can cause many organs to fail. We recommend further studies to confirm the effectiveness of ivermectin in preventing COVID- 19 rather than dismiss it on the basis of insufficient evidence. Studying is very easy, does not take much time and does not cause economic or health burden. This also does not require special equipment or abilities except for volunteers to join through the investigation.

Biography

Dr A Hegazy is a Professor of Human Anatomy and Embryology and the former chairman of department, Faculty of Medicine, Zagazig University, Egypt & Medical Biotechnology Department, College of Biotechnology, Misr University for Science & Technology (MUST), Egypt. He is also a Consultant of Obstetrics, Gynecology and Infertility. He is also a Professor in King Saud and Majmaah Universities (KSA) 2009-2013 and Misurata, Faculty of Medicine (Libya) 2000. Dr. Hegazy is also a referee of scientific research submitted for promotion of professors in Egyptian Universities (since 2016 till Present). He is a Global Goodwill Ambassador (GGA). He is Editor-in-Chief of: Int J Hum Anat (USA); Women Health and Complications (UK), SAR J Med Case Reports (Bangladesh), Journal of Medical & Advanced Clinical Case Reports (India), International Journal of Science and Research Development, Worldwide Journal of Research (Nigeria), American Journal of Medical Sciences and Pharmaceutical Research & Cloning & Transgenesis (USA).

Publications

1. Hegazy AA, Hegazy RA. COVID-19: Virology, pathogenesis and potential therapeutics. Afro-Egyptian Journal of Infectious and Endemic Diseases. 2020 Jun 1;10(2):93-9.
2. Shouman WM, Hegazy AA, Nafae RM, Ragab MI, Samra SR, Ibrahim DA, Al-Mahrouky TH, Sileem AE. Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomized Clinical Trial. Journal of Clinical and Diagnostic Research. 2021 Feb 1;15(2): OC27-OC32.
3. Hegazy AA, Alghamdi MS, Shouman WM, Hegazy RA. Mass Chemoprophylaxis with Ivermectin against COVID-19 Pandemic: Review and Authors' Perspective. Acta Scientific Medical Sciences 2021;5(6): 47-51.
4. Hegazy AA. Ivermectin for COVID-19 prophylaxis. European Journal of Clinical and Experimental Medicine 2021;19 (3): 280–282. Hegazy AA. Skull Sutures as Anatomical Landmarks. (Chapter) In Book "The Sutures of the Skull" 2021 (pp. 129-146). Springer, Cham

2nd World Congress on Immunology
Webinar | January 25, 2022

Citation: Prof. Abdelmonem Awad Hegazy, *Ivermectin Use in COVID-19 Prophylaxis*, World Immunology 2022, 2nd World Congress on Immunology, Webinar | January 25, 2022, 2165-7920:06-03